Shandong Buchang Pharmaceuticals Co Ltd - Asset Resilience Ratio
Shandong Buchang Pharmaceuticals Co Ltd (603858) has an Asset Resilience Ratio of 3.47% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Shandong Buchang Pharmaceuticals Co Ltd balance sheet assets for the complete picture of this company's asset base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Shandong Buchang Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Shandong Buchang Pharmaceuticals Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shandong Buchang Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Shandong Buchang Pharmaceuticals Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥679.28 Million | 3.47% |
| Total Liquid Assets | CN¥679.28 Million | 3.47% |
Asset Resilience Insights
- Limited Liquidity: Shandong Buchang Pharmaceuticals Co Ltd maintains only 3.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shandong Buchang Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shandong Buchang Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424 |
Drug Manufacturers - Specialty & Generic | 2.09% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
Annual Asset Resilience Ratio for Shandong Buchang Pharmaceuticals Co Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Shandong Buchang Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.09% | CN¥403.75 Million ≈ $59.08 Million |
CN¥19.33 Billion ≈ $2.83 Billion |
+0.39pp |
| 2023-12-31 | 1.69% | CN¥354.09 Million ≈ $51.81 Million |
CN¥20.89 Billion ≈ $3.06 Billion |
-1.61pp |
| 2022-12-31 | 3.31% | CN¥726.45 Million ≈ $106.30 Million |
CN¥21.95 Billion ≈ $3.21 Billion |
+1.23pp |
| 2021-12-31 | 2.08% | CN¥498.17 Million ≈ $72.90 Million |
CN¥23.99 Billion ≈ $3.51 Billion |
+0.39pp |
| 2020-12-31 | 1.69% | CN¥386.45 Million ≈ $56.55 Million |
CN¥22.89 Billion ≈ $3.35 Billion |
-0.14pp |
| 2019-12-31 | 1.82% | CN¥386.45 Million ≈ $56.55 Million |
CN¥21.19 Billion ≈ $3.10 Billion |
+1.76pp |
| 2017-12-31 | 0.07% | CN¥13.00 Million ≈ $1.90 Million |
CN¥19.20 Billion ≈ $2.81 Billion |
-0.47pp |
| 2016-12-31 | 0.54% | CN¥100.00 Million ≈ $14.63 Million |
CN¥18.67 Billion ≈ $2.73 Billion |
-- |
About Shandong Buchang Pharmaceuticals Co Ltd
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.